Quick Read Viking Therapeutics surged 26% after VK2735 maintenance data validated monthly and every-other-week dosing schedules, directly addressing the adherence problem plaguing injectable GLP-1s. Obesity peers shrugged at the results, with Structure falling, Lilly gaining 1%, and Novo slipping, as traders read the news as company-specific validation rather than a sector-wide catalyst. With $502 million in cash and two fully enrolled Phase 3 trials, Viking holds leverage to operate on its own timeline rather than accept acquisition terms. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Viking Therapeutics didn't make the cut. Enter your email to see the names that beat VKTX.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.